Clinical Research

To date, a number of publications in peer reviewed journals support the use of NeuroAiD™ in stroke recovery and selected neurosurgical pathologies as a safe and effective medicine at the chronic stage of stroke.

  • Clinical trials on 605 patients recruited between 2 weeks and 6 months after their stroke shows that subjects taking NeuroAiD™ are 2.4 times more likely to regain independence and achieve an average of 25% higher recovery in motor functions versus subjects receiving another well established traditional medicine.(Stroke 2009)
  • A double blind placebo controlled clinical trial which was conducted on 150 subjects having suffered from stroke less than 3 months previously. NeuroAiDTMshowed a better motor recovery than placebo, and was safe as an add-on therapy to standard ischemic stroke medications, especially in severe and moderate cases.(Stroke Research and Treatment , 2011)
  • Neuroaid triggers a significant increase of Cerebral Blood Flow velocity after 3 months treatment. These results, which was associated with a better functional outcome, suggested increased angiogenesis and microcirculation activity as mechanisms of recovery (European Journal of Internal Medicine, 2011)
  • NeuroAiDTM may increase the recovery of vision deficits in post stroke Homonymous Hemianopsia patients. The patients in NeuroAiDTMgroup demonstrated a 50% increase in therapeutic effects as compared to the Piracetam group (Neuronal Regeneration Research, 2011)
  • Case reports on 10 patients who received NeuroAiD after ischemic stroke onset confirmed on imaging recorded a variety of improvements (motor, gait, cognitive) (European Neurology 2009)
  • In a double-blind, placebo-controlled, randomized phase II pilot study to investigate the potential efficacy of the traditional Chinese medicine NeuroAiD (MLC 601) in enhancing recovery after stroke (TIERS), treatment was initiated less than one month post ischemic stroke. NeuroAiD performed better in severe cases (+58% compared to the Placebo panel) and in best responders group (+39% better recovery than in placebo panel) (Cerebrovascular Disease, 2009)

Safety Profile
Neuroaid has well established safety profile. Several clinical trials have established its excellent tolerability both at acute and chronic stages;